Compare HTCR & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HTCR | SILO |
|---|---|---|
| Founded | 2009 | 2010 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Apparel |
| Sector | Technology | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7M | 3.1M |
| IPO Year | 2022 | 2011 |
| Metric | HTCR | SILO |
|---|---|---|
| Price | $1.77 | $1.41 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 12.1K | ★ 44.0K |
| Earning Date | 11-17-2026 | 11-12-2026 |
| Dividend Yield | ★ 145.25% | N/A |
| EPS Growth | ★ 414.29 | 57.98 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,407,229.00 | $72,102.00 |
| Revenue This Year | $118.88 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 39.19 | N/A |
| 52 Week Low | $0.15 | $0.22 |
| 52 Week High | $3.97 | $7.95 |
| Indicator | HTCR | SILO |
|---|---|---|
| Relative Strength Index (RSI) | 29.99 | 20.83 |
| Support Level | N/A | N/A |
| Resistance Level | $2.16 | $4.80 |
| Average True Range (ATR) | 0.12 | 0.11 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 19.61 | 27.00 |
HeartCore Enterprises Inc is a software development company providing solutions for digital transformation (DX). It develops, sells, and maintains CMS and CXM platforms using digital marketing technology, RPA, process mining solutions, myInvenio and Apromore, task mining solution CONTROLIO, and 3D-VR services including Matterport and VR360. The company also provides management consulting, education, services, and support to help customers succeed with the CXM Platform. It operates through two business units, the CX division for customer experience management and the DX division for digital transformation, which provides robotics process automation, process mining, and task mining. Its products include VR360, myInvenio, Apromore, and others, with maximum revenue from the United States.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.